⌕
EyePoint · EYPT · Nasdaq
Tenet 44 · Weak
Compare
$0.31−4.23%At closeTenet 44 · Weak
$0.31−0.01 (−4.23%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

EyePoint (EYPT) Stock

EyePoint (EYPT) closed at $0.31 on Nov 13, 2026; its Tenet Score is 44 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$0.31
Nov 13, 2026
Market cap
$34.8M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
0.31 – 19.11
low → high
Tenet Score
44/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

EyePoint Inc. scores 44/100. Weak. Strongest on value, quality is the soft spot versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
44/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
99
Quality
4
Health
64
Growth
7

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueA+QualityFHealthCGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.3×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
1.1×
price to fiscal 2025 sales
ROE
−222%
TTM through Sep 30, 2026
Operating margin
−776.0%
fiscal 2025, before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
3.30
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 1y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About EyePoint Inc.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release mi…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 44 US ETFs · top wrappers by weightSee all ETFs holding EYPT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is EyePoint in?

EyePoint is in the Healthcare sector and the Drugs industry.

What is EyePoint's Tenet Score?

EyePoint's Tenet Score is 44 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.